Here is an updated version of the summary after different feedback. I changed the parameter from “Safety data” to “Safety” but I’m not satisfied with that namning yet. If someone finds a better word for it let me know.
4 Likes
Curious
#22
I think it would be great to have a section here for rapamycin related biomarkers.
Which biomarkers are relevant for people concerned about the unlikely event negative sideffects?
But also which biomarkers are relvant to follow to track positiv effects?
1 Like
David
#23
@Krister_Kauppi Thank you for trying to organize a confusing topic with using top four and charts with key factors. Also, I appreciate your willingness to have it be template that can change with more input that allows it to evolve and improve:)
Clarity of a dose may help. Longevity dosing is not agreed upon even on this site. We have 20 year olds taking small doses and then multiple variables of EVO, grapefruit juice, washout periods, compounded versions, generic versions from domestic and abroad…and on and on.
I do think a dose of 3mg - 12 mg take weekly / biweekly is a more common and safety or risk of serious adverse events would be appropriate for what you are putting together. Risk of adverse events is how medical studies measure safety. These are just my opinions which could change as this discussion progresses!
2 Likes
约瑟夫
#24
If you are that interested/concerned about “biomarkers” just follow/perform the testing{on yourself] used in the PEARL study.
There is at least one member/user on this forum doing this{the PEARL testing on themselves, outside of the PEARL study]
1 Like
This is my next sketching mini-project is my plan. I would like to create some sort of summary of the side effect profile and how to minimize it and what biomarkers to track. This will be a tough one to fix but I will try to see if I can get it on place.
It’s also interesting that you lift the positive side effects but that is much harder to get a good grip of. This is the thing which researcher are currently trying to find. So that part I will postpone. But next year from two longevity trials we will get some more data to the topic 
2 Likes
To add another parameter of average dose “longevity” regime would be very nice to get in. The rapamycin dose regime I’m quite comfortable to set. I have an IT project ongoing currently which probably could help a lot with this type of summary. My goal is that a first version of the internet based application will be completed next year
2 Likes
These things are hard to handle, but thanks for your efforts.
